Ceribell Secures CMS NTAP for Delirium Monitor System
SUNNYVALE, Calif., Aug. 3, 2026 Ceribell, Inc. has secured a significant reimbursement milestone after the U.S. Centers for Medicare...
ADHD
Advertisement
Supernus Pharmaceuticals and Indivior to Merge in $2.2 Billion CNS Biopharma Deal
ROCKVILLE, Md. & RICHMOND, Va., Aug. 3, 2026 Supernus Pharmaceuticals and Indivior Pharmaceuticals announced they have entered into a...
Otsuka’s SIMTRIYO® Becomes First Approved NDSRI for ADHD
PRINCETON, N.J., July 27, 2026 Otsuka Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) have announced...
Otsuka Wins FDA Approval for First-in-Class SIMTRIYO for ADHD
PRINCETON, N.J. and TOKYO, Japan, July 24, 2026 Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd....
Supernus Marks Five Years of Qelbree FDA Approval with Continued Growth in ADHD Treatment
ROCKVILLE, Md., July 14, 2026 Supernus Pharmaceuticals celebrated the fifth anniversary of the U.S. Food and Drug Administration (FDA)...
Advertisements
Otsuka Reports Positive Phase 3b Results for Centanafadine
TOKYO, Japan & PRINCETON, N.J., June 26, 2026 Otsuka Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Development & Commercialization, Inc....
NeuroSigma Study Reveals Real-Time Brain Effects of eTNS
Los Angeles, California – November 3, 2025 NeuroSigma, Inc., a Los Angeles-based bioelectronics company, has announced a groundbreaking publication...
Advertisement
